Results 91 to 100 of about 2,223,573 (201)

Factors Associated With Long‐Term Survivors With Epidermal Growth Factor Receptor Positive Non‐Small Cell Lung Cancer Treated With First or Second‐Generation Tyrosine Kinase Inhibitors: A Canadian Multi‐Center Cohort

Asia-Pacific Journal of Clinical Oncology, EarlyView.
In a multi‐center Canadian cohort of 577 patients with advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer treated with first/second‐generation TKIs, Asian ancestry and female sex predicted longer survival, while the L858R mutation predicted shorter survival.
Heather Halperin, Amanda J. W. Gibson, Ali Hussein, Mike Sung, Pascale Tomasini, Michelle Dean, Jennifer H. Law, Cheryl Ho, Vishal Navani, Natasha B. Leighl, Desiree Hao   +10 more
wiley   +1 more source

Gemcitabine resistance in a highly metastatic subpopulation of a pulmonary adenocarcinoma cell line resistant to gefitinib

International Journal of Oncology, 2007
The response rates to combination chemotherapy in metastatic non-small cell lung cancer (NSCLC) cases have been reported to be lower than those to induction chemotherapy in locally advanced cases. To understand the relationship between highly metastatic potential and chemosensitivity, we examined the drug sensitivity of a highly metastatic human lung ...
Akira, Takemura, Akihiko, Gemma, Masahiko, Shibuya, Kuniko, Matsuda, Tetsuya, Okano, Michiya, Nara, Rintarou, Noro, Yuji, Minegishi, Akinobu, Yoshimura, Shoji, Kudoh   +9 more
openaire   +3 more sources

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib [PDF]

Proceedings of the National Academy of Sciences, 2005
Non-small cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to the reversible tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Some recurrent tumors have a common secondary mutation in the EGFR
Eunice L, Kwak, Raffaella, Sordella, Daphne W, Bell, Nadia, Godin-Heymann, Ross A, Okimoto, Brian W, Brannigan, Patricia L, Harris, David R, Driscoll, Panos, Fidias, Thomas J, Lynch, Sridhar K, Rabindran, John P, McGinnis, Allan, Wissner, Sreenath V, Sharma, Kurt J, Isselbacher, Jeffrey, Settleman, Daniel A, Haber   +16 more
openaire   +2 more sources

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Metformin sensitizes hypoxia-induced gefitinib treatment resistance of HNSCC via cell cycle regulation and EMT reversal

, 2018
Xiteng Yin,1,2,* Zheng Wei,1,2,* Chuanhui Song,1,2 Chuanchao Tang,1,2 Wenguang Xu,1,2 Yufeng Wang,1,2 Junqi Xie,1,2 Zitong Lin,2,3 Wei Han1,2 1Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Medical School of Nanjing ...
Xie JQ, Lin ZT, Tang CC, Yin XT, Han W, Wang YF, Wei Z, Song CH, Xu WG   +8 more
core  

Health-Related Quality-of-Life in a Randomized Phase Iii First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced Nsclc (Ipass)

, 2012
Introduction: Evaluation of health-related quality-of-life ( HRQoL) and symptom improvement were preplanned secondary objectives for the overall population and posthoc analyses for epidermal growth factor receptor (EGFR ) mutation- positive/negative ...
楊志新;陳育民;郭漢彬, Thongprasert, Sumitra; Duffield, Emma; Saijo, Nagahiro; Wu, Yi-Long; Yang, James Chih-Hsin; Chu, Da-Tong; Liao, Meilin; Chen, Yuh-Min; Kuo, Han-Pin; Negoro, Shunichi; Lam, Kwok Chi; Armour, Alison; Magill, Patrick; Fukuoka, Masahiro   +1 more
core   +1 more source

Lung Cancer Brain Metastasis: Brain Microenvironmental Adaptation, Therapeutic Resistance and Translational Strategies

Cancer Science, EarlyView.
Lung cancer brain metastasis is shaped by dynamic crosstalk among tumor cells, the blood–brain barrier, glial and immune cells, neurons, and metabolic niches. This review integrates these mechanisms with therapeutic resistance, translational models, CNS delivery, and multidisciplinary treatment strategies.
Jun Yang, Junyi Xiong, Li Ying, Yanyang Zeng, Ziqiang Ouyang, Mei Liu, Meihua Li   +6 more
wiley   +1 more source

Table_1_ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC.DOC

, 2018
Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is used clinically as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations, but the inevitable ...
Yi Dai (47974), Hongbo Zhao (539923), Lanxiang Wu (5989886), Honghao Zhou (405068), Jingjing Shi (407360), Yutang Huang (5989883)   +5 more
core   +1 more source

The Mechanism of Gefitinib Resistance Induced by Hepatocyte Growth Factor 
in Sensitive Non-small Cell Lung Cancer Cells in Vitro

Chinese Journal of Lung Cancer, 2013
Background and objective Previous studies have reported that Met might be related to gefitinib resistance in non-small cell lung cancer (NSCLC).
Xianglan XUAN, Changshan AN, Caicun ZHOU
doaj   +1 more source

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source